Choose Injectable Delivery When: Maximum bioavailability and systemic distribution are required Your peptide has a molecular weight exceeding 6,000 Da Precise dosing and reproducible pharmacokinetics are necessary Youre using peptides for bodybuilding or muscle growth The peptide lacks CNS targets Choose Nasal Delivery When: Direct CNS delivery and blood-brain barrier bypass are therapeutic objectives Your peptide is small (under 6,000 Da) and shows adequate nasal bioavailability Rapid onset of action (minutes) is clinically valuable Patient compliance and comfort are primary concerns Youre using neurological peptides like Semax or Selank The FDA has approved several intranasal peptide formulations, including ZAVZPRET for acute migraine treatment, validating this delivery route as pharmaceutically viable

Tel : 609-228-6898 Technical Support : [email protected] Purity & Documentation Data Sheet (275 KB) SDS (252 KB) English - EN (252 KB) Franais - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Espaol - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB) Handling Instructions (2659 KB) References [1]
Common Protocol: CJC-1295: 100200 mcg 12x daily, subcutaneous Ipamorelin: 100200 mcg 12x daily, subcutaneous (often injected together with CJC-1295) Cycle: 812 weeks, can be run longer depending on goals 4
Li Z, Li S, Li K, Jiang X, Zhang J, Liu H